Gottlieb J., Guarino A., Call J., et al: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep54:461-470, 1970
2.
Muggia FM, Creaven P., Hansen H., et al: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): Correlation with preclinical studies. Cancer Chemother Rep56:515-521, 1972
3.
Kuhn J., Burris S., Wall J., et al: Pharmacokinetics of the topoisomerase I inhibitor, SK&F 104864. Proc ASCO9269, 1990
4.
Wall J., Havlin K., Burris H., et al: Phase I study of SK&F 104864, a novel topoisomerase I inhibitor . Proc ASCO9:336, 1990
5.
Investigational Drug Branch: Topotecan clinical brochure. National Cancer Institute , Bethesda, MD, 1989
6.
Sirott M., Saltz L., Young C., et al: Phase I and clinical pharmacologic study of intravenous topotecan . Proc ASCO10:285, 1991
7.
US Department of Health and Human Services : NCI Investigational Drugs-Pharmaceutical Data, 1991. Public Health Service, National Institutes of Health, Bethesda, MD, 1991
8.
Wall J., Burris H., Rodriguez G., et al: Phase I trial of topotecan (SK&F 104864) in patients with refractory solid tumors. Proc ASCO10:261, 1991
